Top

Published in:

01-01-2011 | Original Paper

Serum CCL23 levels are increased in patients with systemic sclerosis

Authors: Koichi Yanaba, Ayumi Yoshizaki, Eiji Muroi, Fumihide Ogawa, Yoshihide Asano, Takafumi Kadono, Shinichi Sato

Published in: Archives of Dermatological Research | Issue 1/2011

Abstract

The aim of this study is to determine serum CCL23 levels and their clinical associations in patients with systemic sclerosis (SSc). Serum CCL23 levels were examined by ELISA in 66 patients with SSc, 20 patients with systemic lupus erythematosus, 20 patients with dermatomyositis, and 33 healthy individuals. Serum CCL23 levels were elevated in SSc patients (389.1 ± 199.2 pg/mL) compared with healthy individuals (94.1 ± 85.6 pg/mL; P < 0.001) and patients with systemic lupus erythematosus (43.4 ± 39.3 pg/mL; P < 0.001) or dermatomyositis (132.1 ± 104.5 pg/mL; P < 0.001). Among SSc patients, there were no differences in serum CCL23 levels between those with limited cutaneous SSc and those with diffuse cutaneous SSc. SSc patients with elevated CCL23 levels were found to have shorter disease duration than those with normal CCL23 levels (P < 0.001). Furthermore, raised CCL23 levels were associated with a higher frequency of pulmonary arterial hypertension (P < 0.05). The results show that serum CCL23 level was increased in the early phase of SSc. CCL23 could be associated with induction of SSc and as such would be a serologically useful marker for disease activity.

Berahovich RD, Miao Z, Wang Y, Premack B, Howard MC, Schall TJ (2005) Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol 174:7341–7351PubMed

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–348CrossRefPubMed

Clements PJ, Lachenbruch PA, Seibold JR et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobeservar variability in 3 independent studies. J Rheumatol 20:1892–1896PubMed

Famularo G, Procopio A, Giacomelli R et al (1990) Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol 81:368–372CrossRefPubMed

Fleischmajer R, Perlish JS, Reeves JRT (1977) Cellular infiltrates in scleroderma skin. Arthritis Rheum 20:975–984CrossRefPubMed

Grassegger A, Schuler G, Hessenberger G et al (1998) Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 139:639–648CrossRefPubMed

Han KY, Kim CW, Lee TH, Son Y, Kim J (2009) CCL23 up-regulates expression of KDR/Flk-1 and potentiates VEGF-induced proliferation and migration of human endothelial cells. Biochem Biophys Res Commun 382:124–128CrossRefPubMed

Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328–332PubMed

Hwang J, Son KN, Kim CW et al (2005) Human CC chemokine CCL23, a ligand for CCR1, induces endothelial cell migration and promotes angiogenesis. Cytokine 30:254–263CrossRefPubMed

10.

LeRoy EC, Krieg T, Black C et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202–205PubMed

11.

Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33:275–284PubMed

12.

Molteni M, Della Bella S, Mascagni B et al (1999) Increased interferon-gamma (IFN-γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud’s phenomenon. Clin Exp Immunol 116:164–168CrossRefPubMed

13.

Nardelli B, Morahan DK, Bong GW, Semenuk MA, Kreider BL, Garotta G (1999) Dendritic cells and MPIF-1: chemotactic activity and inhibition of endogenous chemokine production by IFN-gamma and CD40 ligation. J Leukoc Biol 65:822–828PubMed

14.

Nardelli B, Tiffany HL, Bong GW et al (1999) Characterization of the signal transduction pathway activated in human monocytes and dendritic cells by MPIF-1, a specific ligand for CC chemokine receptor 1. J Immunol 162:435–444PubMed

15.

Needleman BW, Wigley FM, Stair RW (1992) Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor-α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 35:67–72CrossRefPubMed

16.

Novak H, Muller A, Harrer N, Gunther C, Carballido JM, Woisetschlager M (2007) CCL23 expression is induced by IL-4 in a STAT6-dependent fashion. J Immunol 178:4335–4341PubMed

17.

Rioja I, Hughes FJ, Sharp CH et al (2008) Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 58:2257–2267CrossRefPubMed

18.

Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP (1984) Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 27:645–653CrossRefPubMed

19.

Sato S, Ihn H, Kikuchi K, Takehara K (1994) Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 37:391–394CrossRefPubMed

20.

Scharffetter K, Lankat-Buttgereit B, Krieg T (1988) Localization of collagen mRNA in normal and scleroderma skin by in situ hybridization. Eur J Clin Invest 18:9–17CrossRefPubMed

21.

Son KN, Hwang J, Kwon BS, Kim J (2005) Human CC chemokine CCL23 enhances expression of matrix metalloproteinase-2 and invasion of vascular endothelial cells. Biochem Biophys Res Commun 340:498–504CrossRefPubMed

22.

Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444CrossRefPubMed

23.

Steen VD, Powell DL, Medsger TAJ (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196–203CrossRefPubMed

24.

Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590

25.

Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed

26.

Valentini G, Della Rossa A, Bombardieri S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592–598CrossRefPubMed

27.

White B (1996) Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 32:695–708CrossRef

Title: Serum CCL23 levels are increased in patients with systemic sclerosis
Authors: Koichi Yanaba
Ayumi Yoshizaki
Eiji Muroi
Fumihide Ogawa
Yoshihide Asano
Takafumi Kadono
Shinichi Sato
Publication date: 01-01-2011
Publisher: Springer-Verlag
Published in: Archives of Dermatological Research / Issue 1/2011
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-010-1078-8

At a glance: The STEP trials

Springer Medicine

Serum CCL23 levels are increased in patients with systemic sclerosis

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

PPARδ agonists suppress angiogenesis in a VEGFR2-dependent manner

Suppression of keloid fibroblast

Dimensions of patient needs in dermatology: subscales of the patient benefit index

Plasma TM2-PK levels in mycosis fungoides patients

Definition of treatment goals for moderate to severe psoriasis: a European consensus

A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results